A golf-course bag still owns the strain
The ping is a bag, not a eureka moment. Satoshi Omura's group at the Kitasato Institute in Tokyo treated soil collection as a habit, not a hunt for a headline.
Streptomyces already had a Nobel in the family - Selman Waksman's streptomycin - so Omura's bet was not romantic. Soil microbes poison their neighbours. Some of those poisons become drugs. The work is volume: thousands of cultures, most of them dead ends, a short list of broths worth shipping. From many thousand isolates he kept about fifty that looked promising. One of those fifty, sent in 1974, carried strain MA-4680, later catalogued as Streptomyces avermitilis and, after a 2002 phylogenetic pass, proposed as Streptomyces avermectinius. The sample came from ground near a golf course bordering the ocean at Kawana.
Merck's people, and later Omura himself in the Nobel lecture, said the same awkward fact out loud: exhaustive searches never found another avermectin-producing organism. The entire human and veterinary tree hangs on that one isolate. That is why this desk files the origin as a ping rather than a platform. A platform would have turned up twice. A ping is a single hit that has to be cultured, shipped, and defended. If you want the molecule's later clinical life, start here and then move to the Stromectol 3 mg monograph - do not start with a social post that skips the bag.
Fifty shipped cultures, one mouse cleared
| Desk column | Omura / Kitasato | Campbell / Merck |
|---|---|---|
| Ping they owned | Soil isolate MA-4680 | Mouse anthelmintic screen |
| What they could not do alone | In-animal worm kill at scale | Find the organism in Japan |
| Output that moved | Shipped cultures, fermentation notes | Avermectin identified, then edited |
| Later stamp | Shared 2015 Nobel | Shared 2015 Nobel |
Kitasato could grow the organism and describe the fermentation. It could not, at scale, ask whether a broth killed worms living inside an animal. That half of the job sat with William Campbell's parasitology group at Merck Sharp & Dohme Research Laboratories. Boyd Woodruff was posted alongside the Tokyo bench to keep the collaboration from becoming a polite exchange of letters. The screen they used was blunt and fast: mice infected with Nematospiroides dubius, later Heligmosomoides, fed a culture, then watched for vanished worms and vanished eggs.
One of the first fifty specially selected microorganisms cleared the gut. Unpurified broth killed the intestinal worms and wiped the faecal egg signal. Isolation chemists then had to name the causal stuff. It was not one molecule. Analytical work showed a complex of eight closely related structures, later called the avermectins, with a family resemblance to the milbemycin pesticides. Campbell's lecture is dry about the next step: fermentation people coaxed the bacterium to make more, synthetic people made hundreds and then thousands of relatives, and parasitologists ranked them. The ping had become a trace - a partnership with two benches and one organism that still has not been re-found.
Hydrogen at 22-23, and a name that died
The bacterium's product is not the tablet. The tablet is a hydrogenation of one bond, chosen after a grind of analogues.
Merck's chemists added hydrogen at the carbon 22-23 position of selected avermectins. The resulting pair - at least 90 percent 22,23-dihydroavermectin B1a and less than 10 percent B1b - is ivermectin. Campbell wrote that the logical name was hyvermectin, until someone noticed that in some languages 'hyver' means testicle. The bottle became ivermectin. The American Chemical Society later summarised the analogue hunt as a 25-fold potency gain over the worm drugs then on the shelf, with a cleaner safety margin in the host. That is the whole point of a natural-product lead: you do not swallow the broth; you swallow the edit.
US Stromectol is that edit pressed as a 3 mg tablet - microcrystalline cellulose, pregelatinized starch, magnesium stearate, butylated hydroxyanisole, citric acid. The 3 mg chip is the unit that later onchocerciasis programmes counted into weight bands. History people sometimes talk as if 'ivermectin' arrived fully formed from dirt. It did not. Dirt gave a family. A hydrogenation gave a medicine. A tablet strength gave a countable object. The working card on this site is about that object. This page is about why the object exists at all.
Ivomec years before a human river file
The first market was veterinary, in the early 1980s. Cattle, sheep, horses, dogs - heartworm included - took the molecule years before a person with river blindness swallowed a 3 mg chip. Ivomec and its cousins became a bestseller in animal health. That chapter is not a footnote and it is not a license. It proved the chemistry worked in living hosts, paid for the human programme, and left a residue that later confused people: paste formulated for a 500 kg animal sitting on a farm-shop shelf next to a rumour.
Campbell had already flagged a human possibility while the veterinary file was still the main commercial story. Onchocerca volvulus, the filarial worm behind river blindness, looked like a target because the drug hammered microfilariae - the larval stage in skin and eye - even though it left the long-lived adults in their nodules. That gap is the reason onchocerciasis became a repeat-dose public-health file rather than a one-pill cure story. The Edinburgh desk flags it here so the history does not pretend the 1987 human approval was a sudden conversion. It was a second market built on a first one, with a different endpoint: skin-snip counts and sight, not a feedlot.
Aziz in West Africa, then an open pledge
Mohammed Aziz at Merck, working with WHO, designed and ran the West Africa clinics that moved the molecule from a veterinary win to a human onchocerciasis file. Those studies - later summarised on the US label as randomised, double-blind, placebo-controlled and comparative work in endemic West Africa, with diethylcarbamazine citrate as the old comparator - are the trial carton's job. This page only needs the hinge: once the clinics showed a single oral dose could crash skin microfilariae for months, the commercial problem flipped. The people who needed the 3 mg chips lived in places that could not buy them at a patent price.
In October 1987 Merck's then-CEO Roy Vagelos announced the company would donate Mectizan - as much as needed, for as long as needed - to control river blindness. The Mectizan Donation Program and its expert committee were stood up as an independent secretariat at the Task Force for Global Health in Atlanta, not as a marketing desk inside Rahway. That open-ended wording matters. A five-year gift dies. An open pledge lets ministries plan annual mass drug administration. Vector control under WHO's Onchocerciasis Control Programme had already spent a generation larviciding blackfly rivers in West Africa. MDA with a donated 3 mg tablet became the tool that could travel where spraying could not. The Mectizan programme history and the 2015 Nobel press release both treat that pledge as the moment the soil ping became a public-health file.
Colombia first, then three more closures
Elimination is a verification, not a vibe. WHO asks for interrupted transmission plus years of surveillance before it stamps a country.
Omura's group ships a short list of cultures; MA-4680 is among the first fifty.
Campbell's mouse screen finds a broth that clears Nematospiroides; avermectins are isolated.
Ivermectin launches in animals and becomes a veterinary bestseller.
Human onchocerciasis use plus Merck's open Mectizan pledge; MDP secretariat opens.
WHO verifies elimination in Colombia, then Ecuador, Mexico, and Guatemala.
Omura and Campbell share the Nobel Prize in Physiology or Medicine with Tu Youyou.
The Onchocerciasis Elimination Program for the Americas, later sponsored by The Carter Center, coordinated six historically endemic countries: Brazil, Colombia, Ecuador, Guatemala, Mexico, and Venezuela. Foci were smaller and more isolated than the African belt, which made high geographic and therapeutic coverage possible. Colombia stopped treatment, ran post-treatment surveillance, and became the first country in the world to receive WHO verification that onchocerciasis transmission had been eliminated. Ecuador, Mexico, and Guatemala followed. That is four closed ledgers in the Americas, not a global all-clear. Brazil and Venezuela still had harder Yanomami-area foci on the later maps. Africa remains the large remaining file.
Niger later joined the verified list on the African side, and several other countries have interrupted transmission in individual foci. Lymphatic filariasis borrowed the same donation machinery in co-endemic zones. None of that rewrites the origin story. It shows what a 3 mg onchocerciasis chip can do when coverage is high and the pledge does not expire. It also shows the limit: adults live on, so a country only closes the file after years of suppressed microfilariae and dead blackfly transmission, not after one heroic campaign season. The WHO neglected-tropical-disease pages keep the current scoreboard. This history page stops at the shape of the ledger, not today's weekly count.
A 2015 medal does not widen the label
October 2015: the Nobel committee split the Physiology or Medicine prize. Omura and Campbell for avermectin, Tu Youyou for artemisinin. The citation was nature-derived therapies against devastating parasitic diseases. The lag was ordinary for this prize. The committee waits until impact is past argument. By 2015 the Mectizan file had decades of MDA, billions of treatments in the programme's own accounting, and those first verified closures. The medal is a stamp on a finished history, not a hunting license for new diseases.
This Edinburgh desk flags the misuse of that stamp. A soil-to-Nobel arc is catnip for people who want the tablet to be a general elixir. The history does not say that. It says one organism, one edit, one donated 3 mg chip, one larval target in onchocerciasis, and a public-health machine built around annual counts. Viral claims that treat the medal as proof the molecule 'must work' against a respiratory virus are a category error. The trial carton on this site posts the negative hospital endpoints. The working card posts the weight bands. This page posts the origin and then stops. If you need a clinician's byline on the whole set, Dr. Julian Osei signs the consult below from the infectious-disease side of this desk.
How this desk posts a soil history
Ping the bag. Trace the two benches and the hydrogenation. Flag the veterinary paste and the medal-as-license move. Post the river-blindness file: 1987 approval, open pledge, MDA, verified closures. That is the method on this page, and it is why the prose does not walk the monograph's circuit of mechanism, pharmacokinetics, and a bottom line. Those belong on the drug page. Sibling journal pieces keep the skin-snip arithmetic and the 3 mg count versus 150-200 mcg/kg in their own genres.
Readers who want a moral usually ask whether dirt can still deliver medicines. Sometimes. The easy Streptomyces finds were skimmed generations ago. Ivermectin remains a reminder that a stubborn culture collection plus an animal screen can beat a slide deck. It is also a reminder that a medicine's reputation is earned in a named disease. Onchocerciasis gave Stromectol 3 mg its human file. Nothing in Kawana, Rahway, or Stockholm automatically transfers that file to a different pathogen. Bring a named parasite to your own clinician before anyone counts chips. This desk is teaching, not a pharmacy, and Edinburgh is a byline city, not a dispensary.